Prescribing information

 

_

Please use the links below to access the electronic version of resources for Tafinlar + Mekinist. If electronic copies or hard copies are required, please contact your Novartis Representative.

 

Screenshot from the video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar + Mekinist

Video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar + Mekinist

Professor Caroline Robert presents the combined COMBI-d/v 5-year data in the metastatic melanoma setting.

Watch 


Preview of 'Your guide to managing pyrexia'

Your guide to managing pyrexia

Management guide to assist healthcare professionals with managing any pyrexia their patients may experience while on treatment

Preview


Screenshot from the video: Dr Paul Nathan discusses the COMBI-AD trial

Video: Dr Paul Nathan discusses the COMBI-AD trial 

Dr Paul Nathan discusses the use of Tafinlar + Mekinist in an adjuvant setting

Watch 


TMC20-C004j May 2020
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]